Loading
Engineer T cells against CD30 for the few patients who fail brentuximab, PD-1 blockade and transplant.
For the few patients with Hodgkin lymphoma who relapse after brentuximab vedotin, PD-1 blockade and transplant, this idea proposes CAR-T cells engineered against CD30. CD30 is expressed on nearly all Reed-Sternberg cells, shed CD30 does not block binding at therapeutic doses, and the inflamed microenvironment supports CAR-T trafficking. Phase 1/2 studies at UNC and Baylor and of the Tessa Therapeutics TT11 product produced responses and complete remissions in a substantial share of patients, although durability was modest, and the pivotal CHARIOT study was halted for business reasons in 2023 to 2024. The hypothesis is that CD30 CAR-T after PD-1 failure yields durable remissions and that PD-1 blockade prolongs persistence, tested in a randomised phase 2, at an early clinical stage.
One of the most cited trial reports Europe PMC returns for CD30 in Hodgkin lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited reviews Europe PMC returns for CD30 in Hodgkin lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
One of the most cited trial reports Europe PMC returns for CD30 in Hodgkin lymphoma, so it is a natural first reading for anyone weighing the idea it is linked from. The record was linked automatically by title and abstract; read the abstract above and the paper itself before relying on any figure.
Shares CD30, Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares Relapsed and refractory classical Hodgkin lymphoma, Hodgkin lymphoma.
Shares CD30, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Hodgkin lymphoma.
Shares CD30, Hodgkin lymphoma.